Side effects of atypical antipsychotic drugs

Current Pharmaceutical Design

Volumn 10, Issue 18, 2004, Pages 2219-2229

  Ananth, J ^a,b   Parameswaran, S ^a   Gunatilake, S ^a  

^a Metropolitan State Hospital   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Diabetes with antipsychotic drugs; Diabetic ketoacidosis with antipsychotic drugs; Differential effect of antipsychotic induced weight gain; Hyperglycemia with antipsychotic drugs; Weight gain as a side effect of antipsychotic drugs

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; C PEPTIDE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; DEXAMPHETAMINE; DEXFENFLURAMINE; FATTY ACID; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; INSULIN; LEPTIN; MAZINDOL; METFORMIN; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PERPHENAZINE; PHENMETRAZINE; PHENTERMINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIORIDAZINE; TRIACYLGLYCEROL; UNINDEXED DRUG; ZIPRASIDONE;

BEHAVIOR THERAPY; BODY MASS; CELL MEMBRANE FLUIDITY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIET THERAPY; DRUG POTENCY; EATING HABIT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INCREASED APPETITE; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; HUMANS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 3042635724     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384088     Document Type: Review

References (164)

1. Black DW, Fisher R. Mortality in DSM III-R schizophrenia. Schizophr Res 1992; 7: 109-116.
2. Brown S. Excess mortality of schizophrenia. A metaanalysis. Br J Psychiatry 1997; 171: 502-508.
3. Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945; 102: 108-110
4. Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 1946; 56: 74-78.
5. Mukharjee S, Schnur DB, Reddy R. Family history of type II diabetes in schizophrenic patients. Lancet 1989; 1: 405.
6. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994, National Center for Health Statistics. Vital and Health Statistics 1995; 10(193).
7. Mukharjee S, Decina P, Bocola V. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73.
8. Keskiner A, El Toumi A, Bousquet T. Psychotropic drugs, diabetes, and chronic mental patients. Psychosomatics 1973; 14: 176-181.
9. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first episode, drug naïve patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
10. Chartan FBE, Bartlett NG. The effect of chlorpromazine on glucose tolerance. J Ment Sci 1955; 101: 351-353.
11. Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. JAMA 1956; 162: 1651
12. Moraczewski AS, DuBuois KP. The influence of chlorpromazine on intermediary carbohydrate metabolism. Arch Int Pharmacodyn 1959; 120(2): 201-221.
13. Amdisen A. Diabetes mellitus as a side effect of treatment with tricyclic neuroleptics. Acta Psychiatr Scand 1964; 4: 411-414.
14. Schwartz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 1968; 125: 149-150.
15. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes Dis Nerv Syst 1968; 29(12): 827-828.
16. Thonnard-Neumann E. Phenothaizines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 138-142.
17. Ananth J, Gunatilake S, Aquino S, Bach V, Costa J. Are African American patients at a higher risk for olanzapine-induced glucose intolerance? Psychopharmacology (Berl) 2001; 157(3): 324-5.
18. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000; 20(7): 844-847.
19. Wu G, Dias P, Chun W Li G, Kumar S, Singh S. Hyperglycemia, hyperlipemia and periodic paralysis: a case report of new side effects of clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 1395-1400.
20. Rigalleau V, Gatta B, Bonnaudt S, Masson M, Bourgeois ML, Vergnot V, et al. Diabetes as a result of atypical antipsychotic drugs - a report of three cases. Diabet Med 2000; 17: 484-486.
21. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 1994; 151: 1395.
22. Mohan D, Gordon H, Hindley N, Barker A. Schizophrenia and diabetes mellitus. Br J Psychiatry 1999; 174: 180-181.
23. Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, et al. Hepatitis, hyperglycemia, Pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13: 95-98.
24. Kostakoglu AE, Yazici KM, Erbas T, Gevener N. Ketoacidosis as a side effect of clozapine: a Case report. Acta Psychiatr Scand 1996; 93: 217-218.
25. Koren W, Kreis Y, Duchowiczny K, Prince T, Sancovici S, Sidi Y, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997; 31: 168-170.
26. Peterson GA, Bird SL. Diabetic ketoacidosis from clozapine and lithium entreatment. Am J Psychiatry 1996; 153: 737-738.
27. Isakov I, Klesmer J, Masand P. Insulin resistant hyperglycemia induced by clozapine. Psychosomatics 2000; 41: 373-374.
28. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-783.
29. Wood MI. Lethal interaction of clozapine and buspirone. Am J Psychiatry 1997; 154: 1472-1473.
30. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081-1083.
31. Lu HM, Yu HX. Reassessment of the side effect profile of clozapine. Chinese Journal of Clin Psychological Medicine 1997; 7: 298-300.
32. Hagg S, Joelsson IM, Jorndal T, Spight O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294-299.
33. Henderson D, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schonfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities. A five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981.
34. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-443.
35. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999; 22: 1002-1003.
36. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998; 59: 687-689.
37. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 1999; 156: 1471.
38. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. Am J Psychiatry 1999; 156: 970.
39. Bettinger TL, Mendelson SC, Dorson PG, Crimson ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-867.
40. Hayek DV, Huttl V, Reiss J, Schweiger ND, Fuebl HS. Hyperglycemia and ketoacidosis on olanzapine. Der Nrevenarzt 1999; 70: 836-837.
41. Kinon B, Basson B, Gilmore JA, Tollefson GD. Long term olanzapine treatment. Weight change and weight related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100.
42. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000; 41: 369-370.
43. Sobel M, Jaggers ED, Franz MA. New onset diabetes associated with initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556-557.
44. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000; 45(7): 668-9.
45. Pfizer Data on file, 2000.
46. Koller EA, Doraiswamy, P. Olanzapine associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-852.
47. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716-723.
48. Buse JB, Cavozzoni P, Hornbuckle K, Hutchins D, Brier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiology 2003; 56: 164-170.
49. Caro JJ, Ward A, Levington C, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use. A retrospective database analysis. J Clin Psychiatry 2002; 63: 1135-1139
50. Gianfrancisco FD, Grogg AL, Mahout RA, Wang RH, Nasrallah HA. Differential effects of risperidone olanzapine clozapine and conventional antipsychotics on type II diabetes. Findings from a large health plan data base. J Clin Psychiatry 2002; 63: 920-930.
51. Sernyak MJ, Leslie DL, Alarcon RD, Lozonezy MF, Roseneck R. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 4: 561-566.
52. Melson AK, Selke G, Fucetola R, et al. Clozapine can change glucose regulation in schizophrenia independent of body mass index. Abstr Soc Neurosci 1999; 25: 2074.
53. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications J Clin Psychiatry 2001; 62: 15-36
54. Meduna LJ, Gerty FJ, Urse VG. Biochemical disturbances in mental disorders. Arch Neurol Psychiatry 1942; 47: 38-52.
55. Holden RJ, Paukula IS. The link between diabetes ans schizophrenia an immunological explanation. Aust N Z J Psychiatry 1999; 33: 286-287.
56. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 39: 337-345.
57. Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma cells. Neurosci Lett 1999; 274: 151-154.
58. Walters JM, Ward GM, Barton J, Arackal R, Boston RC, Best JD, et al. The effect of norepinephrine on insulin secretion and glucose effectiveness in noninsulin dependent diabetes. Metabolism 1997; 46: 1448-1453.
59. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002; 87(6): 2918-23.
60. Lin Reaven GM, Llithell H, Landsberg I. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
61. Lin Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 236(suppl): 13-22.
62. Dagogo-Jack S, Santiago JV. Pathophysiology of type II diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997; 157: 1802-1817.
63. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106: 475-477.
64. Diebold K, Michel G, Schweizer J, Diebold-Dorsam M, Fiehn W, Kohl B. Are psychoactive drug induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders? Pharmacopsychiatry 1998; 31: 60-67.
65. Ghaeli P, Dufresne RL. Serum triglycerides in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2709-2081.
66. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-770.
67. Ghaeli P, Dufresne RL. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy 1995; 15: 382.
68. Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels and serum triglyceride levels in chronic resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998; 21: 245-250.
69. Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, et al. The impact of clozapine on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999; 22: 98-101.
70. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K Lentz B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Therapy 2003; 10: 348-355.
71. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296
72. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62(5): 347-9.
73. Mittelman SD, Bergman RN. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 2000; 279(3): E630-E637.
74. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22(1): 39-47.
75. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obesity Res 1998; 6(suppl 2): 50s-63s.
76. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemic of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.
77. Gordon HL, Law A, Hohman KE. The problem of overweight in hospitalized psychotic patients. Psychiatr Q 1960; 34: 69-82.
78. Allison DB, Fontaine KR, Moonseong H. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215-220.
79. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry 1983; 44(2): 42-46.
80. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987; 499: 203-215.
81. Baptista T. Bodyweight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16.
82. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002; 71(5): 244-54.
83. Klett CJ, Caffey EM Jr: Weight changes during treatment with phenothiazine derivatives. J Neuropsych 1960; 2: 102-108.
84. Holden JM, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1970; 11(6): 551-561.
85. Branchey MH, Lee JH, Amin R, Simpson GM. High- and low-potency neuroleptics in elderly psychiatric patients. JAMA 1978; 239(18): 1860-1862.
86. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-217.
87. Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacol Bull 1993; 29(2): 249-255.
88. Doss FW. The effect of antipsychotic drugs on body weight: A retrospective review. J Clin Psychiatry 1979; 40: 528-530.
89. Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol 1988; 11(suppl 1):s194-s206.
90. Rockwell WJ, Ellinwood EH Jr, Trader DW. Psychotropic drugs promoting weight gain: health risks and treatment implications. S Med Jour 1983; 76(11): 1407-1412.
91. Brady, KT. Weight gain associated with psychotropic drugs. S Med Jour 1989; 82: 611-617.
92. Bhavnani SM, Levin GM. Antipsychotic agents: A survey of the prevalence, severity and burden of side effects. Int Clin Psychopharmacol 1996; 11(1): 1-12.
93. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001; 62(suppl 7): 22-31.
94. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58(suppl 10): 55-62.
95. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329-338.
96. Naber D, Hippius H. The European experience with clozapine. Hosp Comm Psych 1990; 41: 886-890.
97. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176-185.
98. Hummer M, Kemmler WC, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5(4): 437-440.
99. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6): 358-363.
100. Tran PV, Hamilton SH, Kuntz AJ. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-418.
101. Tohen M, Zarate CA. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59(suppl 1): 38-48.
102. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61(9): 638-642.
103. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-72.
104. Bai YM, Lin CC, Chen JY, Lin CY: Weight gain among patients oil clozapine. Psychiatr Serv 1999; 50(5): 704-705.
105. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825-835.
106. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. NEJM 2002; 348: 16-22.
107. Conley RR, Mahmoud R, Risperidone Study Group. A randomized double-blind study of risperidone and olanzapine in patients with schizophrenia and schizoaffective disorder. Am J Psychiatry 158: 765-774, 2001.
108. Peuskens JA (on behalf-of Risperidone Study Group). Risperidone in the treatment of patients with chronic schizophrenia: a multinational multicenter double-blind parallel group study versus haloperidol. Br J Psychiatry 1995; 166: 712-726.
109. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Slavesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations Acta Psychaitr Scand 1993; 88: 395-402.
110. Csernansky J, Okamoto A. Risperidone versus haloperidol in the prevention of relapse in chronic schizophrenia and schizoaffective disorders: a long-term double blind comparison. Eur Neuropsychopharmacol 1999; 9(suppl 5): s268.
111. Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 2001; 62: 114-116.
112. Arvanitis LA, Miller BG. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42(4): 233-246.
113. Peuskens JA. Comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265-273.
114. Ried LD, Renner BT, Bengston MA, Wilcox BM, Acholunu WW Jr. Weight change after an atypical antipsychotic switch. Ann Pharmacotherapy 2003 Oct; 37(10): 1381-1386.
115. Small JG, Hirsch SR, Arvanitis LA. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997; 54: 549-557.
116. Tandon R, Harrigan E, Zorn S. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159-177.
117. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a six week placebo controlled trial. Neuropsychopharmacol 1999; 20(5): 491-505.
118. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 week placebo controlled trial. Psychopharmacol 1998; 140(2): 173-184.
119. Weiden P, Simpson G, Kramer T. Switching from olanzapine to ziprasidone: clinical effects. Eur Neuropsychopharmacol 1999; 9(suppl 5): s264.
120. Simpson G, Potkin S, Switch Study Group. Switching from risperidone to ziprasidone. Eur Neuropsychopharmacol 1999, 9(suppl 5):s265.
121. Arato MO, O'Connor R, Meltzer H. Ziprasidone investigators Study Group. Ziprasidone:efficacy in the prevention of relapse and in the long term treatment of negative symptoms of chronic schizophrenia. Eur Neuropsychopharmacol 1997; 7(suppl 2): S214.
122. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58(suppl 10): 13-17.
123. Eli Lilly and Company. Zyprexa. In: Physicians' Desk Reference, 53rd Edition. Montvale, NJ, Medical Economics Company, Inc. 1999; 1641-1645.
124. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60(suppl 21): 16-19.
125. Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry 2000; 61(suppl 8): 26-29, discussion 30.
126. Gupta, S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine induced weight gain. Ann Clin Psychiatry 1999; 10: 39.
127. Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacology 2000; 3(4): 339-349.
128. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374(6522): 542-546.
129. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001; 62(suppl 7): 4-10.
130. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995; 269(5223): 546-549.
131. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 22: 263-770.
132. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, lepin, and blood lipids in olanzapine treated patients with schizophrenia or related pychoses. J Clin Psychiatry 2000; 61(10): 742-749.
133. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156(2): 312-314.
134. Ahren B, Larsson H, Wilhelmsson C, Nasman B, Olsson T. Regulation of circulating leptin in humans. Endocrine 1997; 7(1): 1-8.
135. Yamaguchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001; 7: 941-946.
136. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatr Res 2001; 101(3): 277-288.
137. Hauner H. The impact of pharmacotherapy on weight management in type II diabetes. Int J Obes 1999; 23(Suppl 7): S12-S17.
138. Winkelman JW. Schizophrenia, obesity and obstructive sleep apnea. J Clin Psychiatry 2001; 62: 8-11.
139. Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagon YC, Bouchard C. The human obesity gene map: the 2001 update. Obes Res 2002; 10(3): 196-243.
140. Froguel P, Boutin P. Genetics of pathways regulating body weight in the development of obesity in humans. Exp Biol Med (Maywood) 2001; 226(11): 991-996.
141. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13(1): 18-23.
142. Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPA Rgamma) expression in the liver: insights from models of obesity and type II diabetes. Biochem Pharmacol 2002; 63(1): 1-10.
143. Jimerson DC, Lesem MD, Kaye WH, Hegg AP, Brewerton TD. Eating disorders and depression: is there a serotonin connection? Bio Psych 1991; 28(5): 443-454.
144. Grinspoon S, Gulick T, Askari H, Landt M, Lee K, Anderson E, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrin Metab 1996; 81: 3861-3863.
145. Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-Hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry 1991; 48(6): 556-562.
146. Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry 1995; 152: 1073-1074.
147. Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR. The clinical course of osteoporosis in anorexia nervosa. JAMA 1990; 265(9): 1133-1138.
148. Klibanski A, Biller BMK, Schoenfeld D, Herzog DB, Saxe V. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrin Met 1995; 80(3): 898-904.
149. Garattini S, Mennini T, Samain R. Reduction of food intake by manipulation of central nervous serotonin: current experimental results. Br J Psychiatry 1989; 155(suppl 8): 41-51.
150. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A Clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic induced obesity. Br J Psychiatry 1988; 153: 208-213.
151. Wirth A. Long term weight loss with sibutramine: A randomized controlled Trial. JAMA 2001; 286: 1331-1339.
152. Angelescu I Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000; 20: 716-717.
153. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 159: 655-657, 2002
154. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine induced weight gain in schizophrenia. J Clin Psychiatry 2002; 63: 1045.
155. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000; 45(2): 198.
156. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendorine side effects of neuroleptics. J Clin Psychopharmacol 1987; 7: 91-95.
157. Floris M, Lejeunne J Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur J Neuropsychopharmacology 2001; 11: 181-182.
158. Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23: 144-146.
159. Sachetti E, Guarner L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48: 167-168.
160. Stoa-Birketvedt G, Waldum HL, Vonen B, Florholmen J. Effect of cimetidine on basal and postprandial plasma concentrations of cholecystokinin and gastrin in humans. Acta Physiol Scand 1997; 159(4): 321-325.
161. Stoa-Birketvedt G, Pans PN, Gnass R. Cimetidne reduces weight gain and improves metabolic control in overweight patients with type II diabetes. Int J Obes Relat Metab Disord 1998; 22: 1041-1045.
162. Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Design 2003; 9(12): 1023-31.
163. Covelli V, Pellegrino NM, Jirillo E. A point of view: The need to identify an antigen in psyconeu oimmunological disorders. Curr Pharm Design 2003; 9(24): 1951-5.
164. Ito C. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. Curr Pharm Design 2002; 8(2): 147-53.